Structure Therapeutics(US:GPCR)2025-11-06 21:15Financial Performance - Cash, cash equivalents, and short-term investments totaled $799.0 million as of September 30, 2025, expected to fund operations through at least 2027[6] - R&D expenses for Q3 2025 were $59.0 million, up from $32.6 million in Q3 2024, primarily due to increased clinical trial costs[7] - G&A expenses for Q3 2025 were $14.8 million, compared to $13.2 million in Q3 2024, driven by increased employee expenses[8] - Net loss for Q3 2025 was $65.7 million, compared to a net loss of $34.0 million in Q3 2024[9] - Total operating expenses for Q3 2025 were $73.8 million, compared to $45.8 million in Q3 2024[13] - Total liabilities as of September 30, 2025, were $62.1 million, with total shareholders' equity at $770.0 million[15] Clinical Studies - Topline 36-week data from the ACCESS and ACCESS II studies of aleniglipron are on track for readouts by year-end 2025[1] - The ACCESS study enrolled approximately 220 adults, while ACCESS II enrolled about 80 adults, both focusing on obesity treatment with aleniglipron[5] - The company is conducting three supplementary studies to support the design of the Phase 3 program for aleniglipron[4] - ACCG-2671 Phase 1 study initiation is anticipated by year-end 2025, with a second amylin receptor agonist, ACCG-3535, declared as a development candidate[2]